Financial Performance - Total revenue for Q3 2022 reached CNY 1,811,809,605.48, representing a year-on-year increase of 35.35%[4] - Net profit attributable to shareholders for Q3 2022 was CNY 412,654,717.12, a decrease of 21.56% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 420,730,911.64, an increase of 29.02% year-on-year[4] - The company's operating revenue increased by 59.23% year-on-year, reaching ¥5,406,018,843.59, primarily due to increased customer demand and new clinical trial project revenues related to COVID-19[10] - Total revenue for the period reached CNY 5,406,018,843.59, a significant increase from CNY 3,395,015,172.83 in the previous period, representing a growth of approximately 59%[24] - Net profit attributable to shareholders of the parent company is 1,604,658,753.47, compared to 1,781,050,132.72 in the previous period, reflecting a decline of about 9.9%[30] - Total comprehensive income for the current period is 2,122,816,682.93, slightly down from 2,152,521,703.42 in the previous period, indicating a decrease of approximately 1.4%[31] - Basic earnings per share for the current period is 1.86, down from 2.05 in the previous period, a decrease of about 9.3%[31] Assets and Liabilities - The total assets as of the end of the reporting period amounted to CNY 27,140,006,778.09, reflecting a year-on-year growth of 14.32%[4] - Total assets increased to CNY 27,140,006,778.09 from CNY 23,741,171,551.32, reflecting a growth of about 14%[22] - The total liabilities rose to CNY 4,945,848,302.81 from CNY 3,135,974,351.68, an increase of approximately 58%[22] - The total owner's equity amounted to CNY 22,194,158,475.28, up from CNY 20,605,197,199.64, reflecting an increase of about 7.7%[23] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 825,385,230.87, an increase of 13.31% compared to the previous year[4] - Cash flow from operating activities increased to 4,990,906,039.78 from 3,132,970,902.71, representing a growth of approximately 59.2%[33] - Cash flow from investing activities resulted in a net outflow of -2,410,641,100.18, compared to -2,261,400,080.39 in the previous period, indicating a larger outflow[38] - Cash flow from financing activities generated a net inflow of 793,767,270.67, compared to a net outflow of -146,289,027.23 in the previous period, showing a significant turnaround[38] Inventory and Receivables - Accounts receivable increased by 39.76% to CNY 9,685,880.73 due to the receipt of bank acceptance bills from customers[8] - Inventory surged by 475.76% to CNY 35,093,313.34, primarily due to the purchase of experimental materials[8] - The company's inventory significantly increased to CNY 35,093,313.34 from CNY 6,095,078.95, representing a growth of about 475%[18] Investments and Goodwill - Long-term equity investments rose by 134.28% to CNY 1,730,862,925.56, attributed to increased investments in joint ventures[8] - Long-term equity investments surged to CNY 1,730,862,925.56, up from CNY 738,799,229.15, marking an increase of approximately 134%[19] - Goodwill increased by 40.68% to CNY 2,502,676,842.64, mainly due to goodwill generated from newly acquired subsidiaries[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,457[13] - The top shareholder, Ye Xiaoping, holds 20.32% of the shares, totaling 177,239,541 shares[14] Other Financial Metrics - The weighted average return on net assets was 2.18%, down by 0.86% from the previous year[4] - The company's gross profit margin was impacted as operating costs increased by 79.13% to ¥3,237,445,384.18, driven by higher sales and third-party supplier costs[10] - The company reported a 203.43% increase in credit impairment losses, amounting to -¥18,423,588.03, due to increased provisions for bad debts on accounts receivable[10] - The company’s other comprehensive income showed a significant change, with a decrease of 169.85% to ¥108,968,679.69, primarily due to foreign currency translation differences[9] - The company’s financial expenses decreased by 32.28% to -¥118,911,951.41 from -¥175,590,189.04, mainly due to reduced interest expenses from short-term borrowings[50] Audit Status - The report for the third quarter has not been audited[40] - The company did not conduct an audit for the third quarter report[80]
泰格医药(03347) - 2022 Q3 - 季度财报